Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced on September 2, 2026, the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist and spectroscopy expert will bring his scientific expertise in spectroscopy and materials research to support the company's ongoing research and development efforts.
Uwe Perbandt, CEO of Viromed Medical AG, stated, “With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work.” This appointment underscores Viromed's commitment to advancing the medical applications of cold plasma technology, a field with potential implications for wound healing, infection control, and other therapeutic areas.
Prof. Dr. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the Institute’s Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on modern spectroscopic methods, including Raman spectroscopy and ellipsometry, which he uses to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH. His interdisciplinary work has resulted in more than 180 publications with approximately 4,000 citations, including contributions to journals like Physical Review Letters, Nature Physics, and Nature Communications.
The addition of Prof. Dr. Rubhausen to the advisory board is significant for Viromed as it seeks to deepen its understanding of the interaction between cold plasma and biological materials. Cold plasma, or ionized gas, has shown promise in medical applications such as disinfection, wound healing, and even cancer treatment. However, the mechanisms behind these effects are not fully understood. Prof. Dr. Rubhausen’s expertise in spectroscopy could help Viromed analyze these mechanisms more precisely, potentially leading to more effective and safer plasma-based therapies.
For the medical technology industry, this move highlights the growing importance of interdisciplinary collaboration between physics and medicine. By integrating cutting-edge spectroscopic analysis into its research, Viromed is positioning itself at the forefront of scientific innovation in cold plasma applications. This could accelerate the development of new medical devices and treatments, benefiting patients and healthcare providers.
Viromed Medical AG has been listed on the stock exchange since October 2022 and operates through its wholly owned subsidiary Viromed Medical GmbH, focusing on the distribution of innovative cold plasma technology. The company has a broad customer base in the DACH region and beyond. With this new advisory board member, Viromed aims to further advance the use of cold plasma technology in medicine and realize growth potential in the coming years.
Prof. Dr. Rubhausen's appointment is expected to bring valuable insights into material properties and spectroscopic analysis, which are crucial for optimizing plasma-device interactions with biological tissues. His experience with AI-supported analysis workflows for complex datasets may also enable Viromed to harness big data in their research, potentially accelerating discovery and development processes.
As Viromed Medical AG continues to expand its scientific foundation, this strategic addition to its advisory board underscores the company's commitment to evidence-based innovation in medical technology.
